Used as a potent inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK9, this compound plays a significant role in cancer research. It interferes with cell cycle progression and transcription in tumor cells, leading to apoptosis. It is primarily utilized in preclinical studies to evaluate its efficacy in treating various cancers, including leukemia and solid tumors. Its ability to selectively target CDK activity makes it a valuable tool for understanding signaling pathways involved in cell proliferation and survival. Researchers also use it to explore combination therapies with other anticancer agents to enhance treatment outcomes.